medigraphic.com
ISSN 1665-2576 (Print)

2013, Number 2

<< Back Next >>

Rev Mex Cir Endoscop 2013; 14 (2)

Complete resection of an infrequent tumor in the lower third of esophagus by laparoscopy via abdominal

Betancourt-Ángeles M, Andrade-Bucio JA, Alvarado-Ballinas R, Andrade-Bucio AF, Carrillo-Ponce CS, Rodríguez-Ortega MF

Language: English
References: 20
Page: 91-97
PDF size: 689.04 Kb.


ABSTRACT

A gastrointestinal stromal tumor (GIST) is an infrequent tumor with a complex development of disease. This kind of tumor shares a unique characteristic: a KIT-activated mutation, which differentiates them from other mesenchymal malignancies. In half of cases, localization is in stomach, less frequent locations are: omentum, peritoneum, rectum and esophagus. Treatment mainly consist is surgical resection and target therapy. This article’s main objective is to report a totally laparoscopic abdominal resection of a GIST tumor located in lower third of esophagus that was found during a laparoscopic procedure carried on for a different cause than found it. Medical record is: a 48 -years-old- male with previous story of gastro-esophageal reflux disease that underwent to elective laparoscopic fundoplication, during hiatus dissection, the presence of a 5 cm bilobulated-tumor in lower third of esophagus was observed. Excisional biopsy was taken and reported the probability of GIST. We could identify tumor was attached to esophagus’s superficial planes so a complete dissection without breaking tumor’s pseudo-capsule was achieved. Definitive histopathology report was: surgical specimen with free margins of disease and immunohistochemical staining confirmed the GIST diagnosis. Incidence of GIST in lower third of esophagus is a rare and infrequent condition; hence, there are not many reports of totally laparoscopic abdominal resection in tumors bigger than 2 cm; So that’s the purpose of reporting this surgical achieve with satisfactory results. The first of its kind reported in a medical center in the State of Mexico.


REFERENCES

  1. Fletcher DM, Berman JJ, Corless C. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002; 33: 459-465.

  2. Qiu FH, Ray P, Brown K. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family -oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J. 1998; 7: 1003-1011.

  3. Nilsson B, Bumming P, Meis-Kindblom JM. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in Wertern Sweden. Cancer. 2005; 103: 821-829.

  4. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999; 30: 1213-1220.

  5. Wang L, Vargas H, French SW. Cellular origin of gastrointestinal stromal tumors: a study of 27 cases. Arch Pathol Lab Med. 2000; 124: 1471-1475.

  6. Sircar K, Hewlett BR, Huizinga JD. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol. 1999; 23: 377-389.

  7. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998; 11: 728-734.

  8. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analisys of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 2005; 100: 162-168.

  9. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007; 369: 1731-1741.

  10. DeMatteo RP, Lewis JJ, Leung D. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000; 23: 51-58.

  11. Hueman MT, Schulick RD. Management of gastrointestinal stromal tumors. Surg Clin N Am. 2008; 88: 599-614.

  12. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002; 3: 655-664.

  13. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H et al. NCCN task force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007; 5: 1-29.

  14. Gold JS, DeMatteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg. 2006; 244: 176-184.

  15. Gronchi A, Fiore M, Miselli F. Surgery of residual disease following molecular-targeting therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg. 2007; 245: 341-346.

  16. Miettinen M, Sarlomo-Rikala M, Sobin LH. Esophageal stromal tumors: a clinicopathologic, inmunohistochemical and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol. 2000; 24: 211-222.

  17. Alvarado-Cabrero I, Vázquez G, Sierra-Santiesteban FI, Hernández-Hernández DM, Pompa AZ. Clinicopathologic study of 275 cases of gastrointestinal stromal tumors: the experience at 3 large medical centers in Mexico. Ann Diagn Pathol. 2007; 11: 39-45.

  18. Blum MG, Bilimoria KY, Wayne JD, de Hoyos AL, Talamonti MS, Adley B. Surgical considerations for the management and resection of esophageal gastrointestinal stromal tumors. Ann Thorac Surg. 2007; 84: 1717-1723.

  19. Lee HJ, Park SI, Kim DK, Kim YH. Surgical resection of esophageal gastrointestinal stromal tumors. Ann Thorac Surg. 2009; 87: 1569-1571.

  20. Fernández JA, Sánchez-Cánovas ME, Parrilla P. Controversias en el tratamiento quirúrgico de los tumores del estroma gastrointestinal (GIST) primarios. Cir Esp. 2010; 88: 69-80.




2020     |     www.medigraphic.com